Brian Gittleman

First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits β-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast Cancer

Anna Capasso, Stacey M. Bagby, Kyrie L. Dailey et al. · Molecular Cancer Therapeutics · 2019 · 33 citations · Full text

Medicine, Oncology, Pharmacology +17

RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer

John J. Tentler, Julie Lang, Anna Capasso et al. · BMC Cancer · 2020 · 30 citations · Full text

Medicine, Oncology, Pharmacology +17

Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors

S. Lindsey Davis, Anastasia A. Ionkina, Stacey M. Bagby et al. · Clinical Cancer Research · 2020 · 25 citations · Full text

Medicine, Oncology, Pharmacology +15

Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors

Jennifer R. Diamond, Todd M. Pitts, Dana Ungermannova et al. · Molecular Cancer Therapeutics · 2021 · 25 citations · Full text

Pharmacy, Oncology, Pharmacology +16

Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer

Todd M. Pitts, Dennis M. Simmons, Stacey M. Bagby et al. · Cancers · 2020 · 24 citations · Full text

Medicine, Oncology, Pharmacology +17